Orthosiphon stamineus Benth. Methanolic extract enhances the anti-proliferative effects of tamoxifen on human hormone dependent breast cancer

International Journal of Pharmacology

Volumn 5, Issue 4, 2009, Pages 273-276

  Sahib, H B ^a   Ismail, Z ^a   Othman, N H ^b   Abdul Majid, Amin Malik Shah ^a  

^a SCHOOL OF PHARMACEUTICAL SCIENCES   (Malaysia)

^b SCHOOL OF HEALTH SCIENCES   (Malaysia)

Author keywords

Cancer; Estrogen receptor antagonist; Orthosiphon stamineus Benth.; Synergistic activity; Tamoxifen

Indexed keywords

ANGIOGENESIS INHIBITOR; ESTROGEN RECEPTOR; METHANOL; ORTHOSIPHON STAMINEUS EXTRACT; PLANT EXTRACT; TAMOXIFEN; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DETERMINATION; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MONOTHERAPY; ORTHOSIPHON; ORTHOSIPHON STAMINEUS;

EID: 70449353514     PISSN: 18117775     EISSN: 18125700     Source Type: Journal    
DOI: 10.3923/ijp.2009.273.276     Document Type: Article

References (15)

1. Abukhadeir, A.M., M.I. Vitolo, P. Argani, A.M. Demarzo and B. Karakas et al., 2008. Tamoxifen-stimulated growth of breast cancer due to p21 loss. Proc. Natl. Acad.Sci., 105: 926-935.
2. Akowuah, G.A., I. Zahari, I. Norhayati, A. Sadikun and S.M.K. Hamsha, 2004. Sinenstin,eupatorin, 3,-hydroxy-5,6,74,-tetra methoxy flavone and rosmarinic acid content and anti oxidativies effect of Orthosiphon stamineus from Malaysia. Food Chemis., 82: 556-559.
3. Amin, H., D. Christoph, N. Agen, C. Julien, N. Betty, F. Jean-Michel and C.M. Claire, 2000. Progression im MCF7 breast cancer cell tumorigenesity: Compared effect of FGF-3 and FGF-4. Breast Cancer Research and Treatment, 60: 15-28.
4. Gringauz, A., 1997. Introduction to Medicinal Chemistry.How Drugs Act and Why? Wiley-VCH., New York.
5. Hemaiswarya, S. and D. Mukesh, 2006. Potential Synergism of Natural Products in the treatment of cancer. Phytotherapy research, 20: 239-249.
6. Jaganth, I. and L. Ng, 2000. Herbs the Green Pharmacy of Malaysia. Vinpress, Malaysia, pp: 76-77.
7. Jordan, V., 1993. Fourteenth gaddum memorial lecture. A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol., 110: 507-517.
8. Koren, R., D. Rocker, O. Kotestino, U.A. Liberman and A. Ravid, 2000. Synegistic anticancer activity of 1,25 drhydroxyvitamin(D)3 and immun cytokines: the involvement of reactive oxygen species. J. Steroid Brochem. Mol. Brol., 73: 105-112.
9. Krol, W., Z.P. Czuba, M.D. Threadgil, B.D.M. Cunningham and G. Pietsz, 1995. Inhibition of nitric oxide (NO.) production in murine macrophages by flavones. Biochem. Pharmacol., 50: 1031-1035.
10. Lee, W.L., M.H. Cheng, H.T. Chao and P.H. Wang, 2008. The role of selective estrogen receptor modulators on breast cancer: From tamoxifen or raloxifene. Taiwan J. Obstet. Gynecol., 47: 24-31.
11. Sahib, H.B., A F. Aisha, M.F. Yam, M.Z. Asmawi and Z. Ismail et al., 2008. Anti-angiogenic and anti oxidant properties of Orthosiphon stamineus Benth. Methanolic. Int. j. pharmacol., 5: 162-167.
12. Shah, M. and G. Schwartz, 2000. The relevance of drug sequence in combination chemotherapy. Drug Resist Updat, 3: 335-356. (Pubitemid 32118400)
13. Tari, A.M., A.M.Simeone, Y.J. Li, Y. Gutierrez, S. Lai and W.F. Symmans, 2005. Cycloxigenase-2 protien produces tamoxifen and N-(4-hydroxyphenyl) retinamide inhibitory effect in breast cancer cells. Lan Invest, 85: 1357-1367.
14. Tezuka, Y., P. Stampoulis, A. Banskota, S. Awale, K. Tran, I. Saiki and S. Katoda, 2002. Constituent of the vietnamesmedicinal plants Orthosiphon stamineus. Chemis. pharmaceutical Bul., 48: 1711-1719.
15. Thurnher, D.C. T.D. Pelzmann, B. Wannemacher, B. Knerer, M. Wacheck and E. Selzer, 2003. Betulinic acid: A new cytotoxic compound against malignant head and neck cancer cells. Head and Neck, 25: 732-740.